Kirkland Signature AllerClear D 24 HR Tablets Recalled for Moisture Failure
SUN PHARMACEUTICAL INDUSTRIES INC is recalling Kirkland Signature AllerClear D 24 HR (Loratadine and Pseudoephedrine Sulfate) tablets nationwide because the product failed to meet moisture content limits.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard—moisture content outside acceptable limits—is a manufacturing specification issue without documented harm to consumers, consistent with a Low severity rating.
Plain-English summary
SUN PHARMACEUTICAL INDUSTRIES INC is recalling Kirkland Signature AllerClear D 24 HR extended-release tablets containing 10 mg loratadine and 240 mg pseudoephedrine sulfate. The recall affects 46,584 blister packs distributed nationwide within the United States. The product is being recalled due to failed moisture limits during manufacturing quality control.
This is an FDA Class III recall. Consumers who have purchased this product should stop use. The affected product has NDC 63981-724-15 and lot code AC09723 with an expiration date of 11/2022. For more information, consumers may contact the FDA or the recalling manufacturer.
The recalled product
- Product
- KIRKLAND SIGNATURE ALLERCLEAR D 24 HR (LORATADINE AND PSEUDOEPHEDRINE SULFATE)
- Brand
- KIRKLAND SIGNATURE ALLERCLEAR D 24 HR
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Hazard
- moisture-limit-failure
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- AC09723
- Exo
- Date 11/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27